Brachytherapy in organ-preserving treatment of choroidal melanoma: complications and the possibility of their prediction
https://doi.org/10.29413/ABS.2021-6.6-1.4
Abstract
This review analyzed the domestic and foreign literature on brachytherapy of choroidal melanoma using ruthenium ophthalmic applicators. The review highlights the historical aspects of radiation treatment, from the first experience of using ionizing radiation in the treatment of malignant neoplasms to modern methods of brachytherapy; presents the radiobiological foundations of radiation therapy; considers the issues of radiation pathomorphosis, reflecting the nature of pathological changes in the choroidal melanoma tissue during brachytherapy; shows the dependence of the effect of exposure ionizing radiation from the phase of the cycle of cell division; and also describes the presence of changes characteristic of the response to ionizing radiation in unirradiated tissues. The analysis of various post-radiation complications, both early and late, was carried out in some detail, with emphasis on the possibility of predicting and preventing them in real clinical practice. A comparison is made in terms of the frequency of development of various post-radiation complications in the works of domestic and foreign authors, as well as a comparison with the effect of ionizing radiation from other radioactive isotopes. Recommendations of experts are given regarding the correct calculation of the dose to the sclera and medication support, based on many years of experience in the use of ruthenium ophthalmic applicators for brachytherapy of choroidal melanoma. The risks of developing such late complications as radiation maculopathy and radiation neuropathy have been demonstrated, especially in pre-equatorial tumor localization. The possibilities of modern methods of instrumental diagnostics for studying the processes occurring in the area of the tumor, as well as changes in the surrounding tissues, are shown, which determines the feasibility and importance of further study of this issue.
About the Authors
A. A. Bykhovsky
Saint Petersburg Branch of S.N. Fyodorov Eye Microsurgery Federal State Institution
Russian Federation
Russian Federation
Junior Research Officer
Yaroslava Gasheka str. 21, Saint Petersburg 192283, Russian Federation
I. E. Panova
Saint Petersburg Branch of S.N. Fyodorov Eye Microsurgery Federal State Institution
Russian Federation
Russian Federation
Dr. Sc. (Med.), Professor, Deputy Director for Science
Yaroslava Gasheka str. 21, Saint Petersburg 192283, Russian Federation
E. V. Samkovich
Saint Petersburg Branch of S.N. Fyodorov Eye Microsurgery Federal State Institution
Russian Federation
Russian Federation
Ophthalmologist at the 3rd Surgical Unit, Junior Research Officer
Yaroslava Gasheka str. 21, Saint Petersburg 192283, Russian Federation
References
1. Brovkina AF, Khionidi YaN, Nechesnyuk SYu. Sclera necrosis after brachytherapy of choroidal melanoma. Ophthalmology Journal. 2011; 4(3): 78-82. (In Russ.).
2. Brovkina AF. Topical issues of ophthalmic oncology. The Russian Annals of Ophthalmology. 1997; 113(1): 5-7. (In Russ.).
3. Yarovoy AA, Bulgakova ES, Krivovyaz OS, Ushakova TL, Polyakov VG. The efficiency of plaque radiotherapy in the management of retinoblastoma. Fyodorov Journal of Ophthalmic Surgery. 2016; (1): 52-58. (In Russ.).
4. Brovkina AF, Zarubei GD, Valsky VV. Criteria for the effectiveness of brachytherapy of uveal melanomas, complications, and their prevention. The Russian Annals of Ophthalmology. 1997; 113(3): 14-16. (In Russ.).
5. Brovkina AF, Zarubei GD. On the effectiveness of brachytherapy in uveal melanomas. Journal of Ophthalmology (Ukraine). 1993; 48(1): 1-4. (In Russ.).
6. Hungerford JL. Current trends in the treatment of ocular melanoma by radiotherapy. Clin Exp Ophthalmol. 2003; 31(1): 8-13. doi: 10.1046/j.1442-9071.2003.00611.x
7. Wen JC, Oliver SC, McCannel TA. Ocular complications following I-125 brachytherapy for choroidal melanoma. Eye. 2009; 23(6): 1254-1268. doi: 10.1038/eye.2009.43
8. Wilkinson DA, Kolar M, Fleming PA, Singh AD. Dosimetric comparison of 106Ru and 125I plaques for treatment of shallow (#5 mm) choroidal melanoma lesions. Br J Radiol. 2008; 81(970): 784-789. doi: 10.1259/bjr/76813976
9. Karimi S, Arabi A, Siavashpour Z, Shahraki T, Ansari I. Efficacy and complications of ruthenium-106 brachytherapy for uveal melanoma: A systematic review and meta-analysis. J Contemp Brachytherapy. 2021; 13(3): 358-364. doi: 10.5114/jcb.2021.106191
10. Kaprin AD, Mardynsky YuS. Therapeutic radiology: National guidelines. Moscow: GEOTAR-Media; 2018. (In Russ.).
11. Brovkina AF. Ophthalmic oncology. Мoscow: Meditsina; 2002. (In Russ.).
12. Avetisov SE. Ophthalmology: National guidelines. Мoscow: GEOTAR-Media, 2019. (In Russ.).
13. Joyner MS. Fundamentals of clinical radiobiology. Moscow: BINOM. Laboratoriya znaniy; 2013. (In Russ.).
14. Dedenkov AN, Pelevina II, Saenko AS.Predicting tumor responses to radiation and drug therapy. Moscow: Meditsina; 1987. (In Russ.).
15. Kraevsky NA, Smolyannikov AV, Sarkisov DS. (eds). Pathological diagnosis of human tumors. Moscow: Meditsina, 1993. (In Russ.).
16. Vazhenin AV, Panova IE. Selected issues of ophthalmic oncology. Moscow: Izdatelstvo RAMN; 2006. (In Russ.).
17. Pak BJ, Chu W, Lu SJ, Kerbel RS, Ben-David Y. Lineagespecific mechanism of drug and radiation resistance in melanoma mediated by tyrosinase-related protein. Cancer Metastasis Rev. 2001; 20(1-2): 27-32. doi: 10.1023/a:1013175516793
18. Apte RS, Niederkorn JY, Mayhew E, Alizadeh H. Angiostatin produced by certain primary uveal melanoma cell lines impedes the development of liver metastases. Arch Ophthalmol. 2001; 119(12): 1805-1809. doi: 10.1001/archopht.119.12.1805
19. Yarmonenko SP. Radiobiology of humans and animals. Moscow: Vysshaya shkola; 1988. (In Russ.).
20. Zedgenidze GA, Aliev BM. Radiotherapy for outpatients. Tashkent: Meditsina; 1988. (In Russ.).
21. Brovkina AF, Keshelava VV. The result of combined radiation therapy for choroidal melanomas. The Russian Annals of Ophthalmology. 2001; 117(3): 3-5. (In Russ.).
22. Terentyeva LS, Vit VV, Shambra VV, Kotova VA, Gushcha GP. New possibilities of organ-preserving treatment of iridociliary zone melanomas. Journal of Ophthalmology (Ukraine). 1993; 1: 11-15. (In Russ.).
23. Brovkina AF, Keshelava VV, Fridman FE, Fishkin YuG. Combined radiation therapy for uveal melanomas. The Russian Annals of Ophthalmology. 1997; 113(2): 10-12. (In Russ.).
24. Terentyeva LS, Fokin VP. Possibility of organ-preserving treatment of large uveal melanomas. Journal of Ophthalmology (Ukraine). 1989; 6: 338-341. (In Russ.).
25. Shields CL, Cater J, Shields JA, Chao A, Krema H, Materin M, et al. Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: Tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol. 2002; 120(7): 933-940. doi: 10.1001/archopht.120.7.933
26. Yarovoi AA, Linnik LF, Semikova TS, Magaramov DA, Bulgakova ES. Brachytherapy with simultaneous transpupillar diodelaser thermotherapy and independent brachytherapy in treatment of choroidal melanoma: comparative analysis. Russian Journal of Clinical Ophthalmology. 2005; 1: 18. (In Russ.).
27. Lushnikov EF. Radiation pathomorphosis of human tumors. Moscow: Meditsina; 1977. (In Russ.).
28. Vit VV. Radiation pathomorphosis of malignant melanomas of the human uveal tract. Journal of Ophthalmology (Ukraine). 1989; 6: 321-325. (In Russ.).
29. Reinhold HS, Fajardo LF, Hopewell JW. The vascular system. In: Altman KI, Lett JT. Advances in radiation biology. Relative radiation sensivities of human organ systems. Part II. San Diego: Academic Press; 1990; 14: 177-226.
30. Fajardo LF, Steward JR. Patogenesis radiation-induced myocardial fibrosis. Lab Invest. 1973; 29: 244-257.
31. Fajardo LF, King SB, Crocev IR, Mould RF. Radiation injury to blood vessels. Vascular brachytherapy. 1996.
32. Fajardo LF. Berthrong M. Vascular lesions following radiation. Patol Ann. 1988; 23(Pt 1): 297-330.
33. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003; 300(5622): 1155-1159. doi: 10.1126/science.1082504
34. Privalov AV, Vazhenin AV. Complications of combined treatment in preoperative radiation. 99 questions and answers. Chelyabinsk; 2002. (In Russ.).
35. Bardychev MS, Tsyb AF. Local radiation damage. Moscow: Meditsina; 1985. (In Russ.).
36. Lofl er KU, Simon JC, Wutting C. Antigen musterbeim Aderhaut melanom in Korrelationzum Immuns zinttigraphie. Ophtalmologie. 1995; 95(5): 723-727.
37. Shields CL, Naseripour M, Cater J, Shields JA, Demirci H, Youseff A, et al. Plaque radiotherapy for large posterior uveal melanomas (= 8-mm thick) in 354 consecutive patients. Ophthalmology. 2002; 109(10): 1838-1849. doi: 10.1016/s0161-6420(02)01181-8
38. Gunduz K, Shields CL, Shields JL, Cater J, Freire JE, Brady LW. Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol. 1999; 117(5): 609-614. doi: 10.1001/archopht.117.5.609
39. Caminal M, Casany M, Fabregas J, Cope C, Guedea F. Results of Iodine-125 radiotherapy in the treatment of uveal melanoma. Arch Soc Esp Oftalmol. 2002; 77(1): 29-38.
40. Gunduz K, Shields CL, Shields JL, Cater J, Freire JE, Brady LW. Plaque radiotherapy for uveal melanoma with predominant ciliary body involvement. Arch Ophthalmol. 1999; 117(2): 170-177. doi: 10.1001/archopht.117.2.170
41. Summanen P, Immonen I, Kiveld T, Tommila P, Heikkonen J, Tarkkanen A. Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma. Br J Ophthalmol. 1996; 80(8): 732-739. doi: 10.1136/bjo.80.8.732
42. Hermann RM, Pradier O, Lauritzen K, Ott M, Schmidberger H, Hess CF. Does escalation of the apical dose change treatment outcome in radiation of posterior choroidal melanomas with Ru-106 plaques? Int J Radiat Oncol Biol Phys. 2002; 52(5): 1360-1367. doi: 10.1016/s0360-3016(01)02763-8
43. Rouberol F, Roy P, Kodjikian L, Gerard JP, Jean-Louis B, Grange JD. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years’ experience with beta-rays). Am J Ophthalmol. 2004; 137(5): 893-900. doi: 10.1016/j.ajo.2003.12.032
44. Sagoo MS, Shields CL, Emrich J, Mashayekhi A, Komarnicky L, Shields JA. Plaque radiotherapy for juxtapapillary choroidal melanoma treatment complications and visual outcomes in 650 consecutive cases. JAMA Ophthalmol. 2014; 132(6): 697-702. doi: 10.1001/jamaophthalmol.2014.111
45. Zarubei GD, Valsky VV, Borodin YuI. Neuroretinopathy after brachytherapy of uveal melanomas. Russian Journal of Clinical Ophthalmology. 2000; 3(1): 71. (In Russ.).
46. Brovkina AF, Khionidi YaN. Late complications of choroidal melanoma brachytherapy and possibility of their prevention. The Russian Annals of Ophthalmology. 2018; 134(1): 4-11. (In Russ.).
47. Finger PT. Tumor location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol. 2000; 84(9): 1068-1070. doi: 10.1136/bjo.84.9.1068
Review
For citations:
Bykhovsky A.A., Panova I.E., Samkovich E.V. Brachytherapy in organ-preserving treatment of choroidal melanoma: complications and the possibility of their prediction. Acta Biomedica Scientifica. 2021;6(6-1):31-40. (In Russ.) https://doi.org/10.29413/ABS.2021-6.6-1.4
Views:
943
Email this article 
